Synlogic (NASDAQ:SYBX) Share Price Passes Below Fifty Day Moving Average – Here’s Why

Posted by Dante Gardener on Jun 28th, 2026

Synlogic, Inc. (NASDAQ:SYBX – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.67 and traded as low as $0.6112. Synlogic shares last traded at $0.68, with a volume of 1,360 shares trading hands.

Synlogic Stock Performance

The firm’s 50-day moving average price is $0.67 and its 200 day moving average price is $0.75. The company has a market cap of $7.95 million, a price-to-earnings ratio of -2.62 and a beta of 0.56.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Synlogic by 116.7% during the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 46,117 shares during the period. Citadel Advisors LLC acquired a new position in Synlogic in the third quarter valued at about $49,000. Finally, DRW Securities LLC bought a new position in Synlogic during the fourth quarter worth about $27,000. Institutional investors and hedge funds own 63.40% of the company’s stock.

About Synlogic

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.